United States Food and Drug Administration
FDA Approves Axsome’s Symbravo for Acute Migraine Treatment, Overcoming 2022 Rejection
Symbravo, Axsome Therapeutics, FDA approval, acute migraine treatment, meloxicam, rizatriptan, MoSEIC technology
Abbott’s Spinal Cord Stimulation Systems Demonstrate Long-Term Efficacy in Chronic Pain Management
Abbott, spinal cord stimulation, chronic pain, BurstDR stimulation, Proclaim Plus, Proclaim XR, FDA approval, non-surgical back pain
FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi
Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline
Senate Hearing for RFK Jr. Amid Strong Public Support for Vaccine Access
RFK Jr., Senate hearing, vaccine access, public support, FDA-approved vaccines, Department of Health and Human Services nomination
FDA Postpones Opioids Advisory Committee Meeting and Cancels Kidney Drug Review
FDA, advisory committee, postponement, cancellation, opioids, kidney drug, regulatory meetings
FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease
Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist
Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer
Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo
FDA Names Dr. Sara Brenner as Acting Commissioner
FDA, Acting Commissioner, Dr. Sara Brenner, Medical Devices, Food Safety
Takeda to Discontinue Uloric: A Gradual Decline of the Gout Medication
Takeda, Uloric, gout medication, discontinuation, cardiovascular risks, FDA scrutiny
FDA Delays Decision on Stealth BioTherapeutics’ Elamipretide for Barth Syndrome Until April 2025
Barth Syndrome, Elamipretide, FDA Decision, Stealth BioTherapeutics, Drug Approval Delay